Category: Covid-19 Vaccine

FLINT, MI Vaccine distribution and COVID-19 testing clinics will continue at Flint police mini stations for the immediate future, officials said.

On Wednesdays and Fridays, from April 1 through May 31, Flint police mini stations will continue hosting vaccination and testing clinics.

The North End mini station clinic at 4535 Martin Luther King Avenue will be open on Wednesdays, from 5 p.m. to 8 p.m.

The Dort Mall mini station clinic at 3600 S. Dort Hwy. will operate from 11 a.m. to 2 p.m. on Fridays.

The clinics, supported by the City of Flint as well as the Michigan Department of Health and Human Services, first provided vaccines and COVID-19 testing in February.

The mini stations opened in late October 2021 as part of an initiative by Flint Police Chief Terence Green to engage with the public to help combat crime in the city.

Read more on MLive:

Yard waste collection in Flint to begin on April 4

Victim of alleged assault on Flint school board files protection orders against fellow member, activist

$1.58M coming to mid-Michigan from 2021 recreational marijuana tax

Ethics and Accountability board asks Flint council to do a better job

More:

COVID-19 vaccine and testing clinics will continue at Flint police mini stations - MLive.com

MONTGOMERY, Ala. Protection offered by COVID-19 vaccine decreases over time, and the Alabama Department of Public Health cautions that even in times of low community transmission, the risk for older and immunocompromised persons to become severely ill with COVID-19 is not zero. In order to maintain the highest level of protection from vaccinations, the U.S. Food and Drug Administration (FDA) has authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for individuals ages 50 and older and certain immunocompromised individuals.

The Centers for Disease Control and Prevention (CDC) also updated its recommendations for expanded booster eligibility, as described in a recent news release:https://www.cdc.gov/media/releases/2022/s0328-covid-19-boosters.html.Adults who received a primary vaccine and booster dose of Johnson & Johnsons Janssen COVID-19 vaccine at least 4 months ago may now receive a second booster dose using an mRNA COVID-19 vaccine.

The FDA previously authorized a single booster dose for certain immunocompromised individuals following completion of a three-dose primary vaccination series. This action will now make a second booster dose of these vaccines available to other populations at higher risk for severe disease, hospitalization and death. Emerging evidence suggests that a second booster dose of an mRNA COVID-19 vaccine improves protection against severe COVID-19 and is not associated with new safety concerns.

FDA amended the emergency use authorizations as follows:

A second booster dose of the Pfizer-BioNTech COVID-19 Vaccine or Moderna COVID-19 Vaccine may be administered to individuals 50 years of age and older at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine. A second booster dose of the Pfizer-BioNTech COVID-19 Vaccine may be administered to individuals 12 years of age and older with certain kinds of immunocompromise at least four months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine. These are people who have undergone solid organ transplantation, or who are living with conditions that are considered to have an equivalent level of immunocompromise. A second booster dose of the Moderna COVID-19 Vaccine may be administered at least four months after the first booster dose of any authorized or approved COVID-19 vaccine to individuals 18 years of age and older with the same certain kinds of immunocompromise.

For some immunocompromised persons, this will be a fifth dose of vaccine (three for the primary series and two booster doses). This authorization applies only to the Pfizer-BioNTech and Moderna COVID-19 vaccines and the authorization of a single booster dose for other age groups with these vaccines remains unchanged.

The FDA has determined that the known and potential benefits of a second COVID-19 vaccine booster dose with either of these vaccines outweigh their known and potential risks in these populations.For more information about COVID-19, please visit: https://www.alab.

See original here:

Second COVID-19 vaccine boosters authorized for individuals ages 50 and older and higher-risk individuals - The Cullman Tribune

The discovery and approval of effective and safe covid-19 vaccines has provided a glimmer of hope during a seemingly intractable crisis. The vaccines were rapidly distributed across the globe, with priority given to the most at-risk populations in many rich countries.1 While many have called for the equitable distribution of vaccines across the globe through COVAX, and continue to do so, this continues to be far from the reality. As of 1 April 2022, 64.5% of the worlds population has received at least one dose of the vaccine; yet, this proportion is only 14.5% in low-income countries.2 It is in this context of vast vaccine inequity that we discuss Rwandas vaccination strategy and milestones over the past year.

Today, Rwanda has fully vaccinated over 60% of its population.2 In a continent that is a covid-19 vaccine desert, this result is due to the hard work and early preparation of those in charge of the vaccine programme. Months before receiving covid-19 vaccines in the country, the Scientific Advisory Group and National Task Force for covid-19 vaccination met weekly to devise a vaccination strategy, identify gaps, and strengthen cold chain capacity.3 Following these deliberations, Rwanda bought 437 new refrigerators, refrigerated vehicles, passive containers for transportation and 5 ultra-low temperature freezers to ensure readiness for the Pfizer vaccine which at that time needed be stored at 70C.34 By the time of arrival on 3 March 2021, the country was ready with the capacity to store over 5 million vaccines.

Following scientific advice aligned to the World Health Organisations (WHO) guidelines, Rwanda developed a vaccine priority list that included the most at-riskmedical professionals and community health workers, older populations, individuals with underlying conditionsincluding those in prisons and refugeesand all essential workers.4 As more people were vaccinated in the country, the priority list was expanded to all individuals over 60 and over time, this age limit was reduced to 18 years old.5 This national priority list was conceived rapidly and accurately using a nationwide demographic screening programme up to the community level and an up-to-date registry of non-communicable diseases at the facility level. This list is also currently being applied to the rollout of booster shots.6

To make this equitable and effective distribution a reality, Rwanda adopted a coordinated and organised plan. Every single individual, both within the ministry of health and in implementing partner institutions, knew what to do. More than a month before vaccination started, at least two vaccination teams were appointed at each health facility across the country to ensure that healthcare workers had the capacity to vaccinate, manage, and electronically track the vaccinated.3 Moreover, the location of vaccine delivery was adapted to reach communities that are most at-risk and hard-to-reach. For instance, door-to-door vaccination was adopted for those above 60 and those living with disabilities.7 When the Ministry of Health expanded the eligibility list to include those above 18, the campaign was first focused in Kigali which is the most densely populated region and carries the highest covid-19 burden.5 Afterwards, the delivery was done across the country following these criteria.

While many have claimed vaccine hesitancy to be the major hurdle to covid-19 vaccination in Africa, this is largely inaccurate. According to a 2018 Wellcome Trust study, the Rwandan population has the highest trust in the public health system, which explains the countrys high childhood vaccination rate.89 This high level of trust was further reinforced by the governments open communication. The Ministry of Health worked alongside various partners such as faith-based organizations, NGOs, local authorities, and the media to provide more information on the vaccines and dispel any misinformation. Examples of public engagement channels used include a one-page fact sheet and radio and TV channels.10

One example of the vaccine rollout is on the night of 3 March 2021, 340000 vaccines from COVAX from Pfizer BioNTech and Oxford/AstraZenecaarrived in Rwanda.11 They were kept overnight at the central storage facility and recorded in an electronic registry. By noon of 4 March, the vaccines were distributed to all district hospitals that in turn distributed them to all health centers the same afternoon, using health sector trucks and other modes of safe transport available including military helicopters. The quantity of vaccines allocatedto each district and health facility was based on a list created during the preparatory phase.3 On the morning of 5 March, Rwanda had started vaccinating healthcare workers across the country and within three weeks, Rwanda had vaccinated 348000 people, including doses donated by China at that time.

Rwanda has surpassed the 30% target it had set for the end of 2021 and is well on its way to achieving the 60% target for June 2022, having already vaccinated nearly 60% of its population. It is because of this efficiency and success that Rwanda Biomedical Center was named one of the covid-19 Vaccination Centers of Excellence by Africa Centers for Disease Control and Prevention (CDC).12

Competing interests: none declared.

Provenance and peer review: commissioned, not peer reviewed

Tony Blair Institute for Global Change. Vaccinating Africa: What Governments Can Learn From Rwandas Effective Rollout. https://institute.global/advisory/vaccinating-africa-what-governments-can-learn-rwandas-effective-rollout

Read the original post:

Rwanda's success in rolling out its covid-19 vaccination campaign is a lesson to us all - The BMJ

U.S. health officials stop shipments of the monoclonal antibody sotrovimab to certain states, Novavax's protein-based vaccine is being tested as a booster in two new clinical trials, and more in this week's roundup of Covid-19 news.

See the original post here:

Covid-19 roundup: WHO monitors rare reports of auditory issues after vaccination - The Daily Briefing

shaunl / Getty Images / iStock

Headache is a common disorder and head pain is a common experience in the lives of almost everyone. The prevalence of headache within one year is 43% in people aged below 50, and on a given day, 6-17% of persons of any age may experience headache. Like all vaccinations, including those aimed to protect against SARS-CoV-2 (the virus responsible of COVID-19), there may be side effects.

Our latest systematic literature review with meta-analysis assesses the occurrences of developing headache after COVID-19 vaccination. Our results are based on 84 clinical trials testing the efficacy, effectiveness and safety of the vaccines that have been developed between 2020 and 2021, for a total of 1.57 million persons receiving one vaccine or a placebo.

In the week after the first administration, 22% of vaccine recipients developed headache while 10% among placebo recipients reported headache. After the second administration, these percentages raise to 29% and to 12% among vaccine and placebo recipients, respectively. Headache is the third most common side effect the most common being pain at injection site.

Generally, duration of headache onset within the first day from injection is below 24 hours, of a moderate intensity, and benefits from treatment with acetylsalicylic acid. It is bilateral (i.e. on both sides of the head) in 7075% of the cases, and 3040% of the patients describe a pulsating quality. Aggravation with activity is the most common accompanying symptom, followed by phono/photophobia (i.e. being bothered by light and noise) and nausea.

Taken as a whole, the features of such a headache do not resemble migraine-like headache in most of the cases; however, in approximately one third of the cases, migrainous features seem to be met, and this appears to be much more common among people with pre-existing migraine.

The causes of headache after vaccination against SARS-CoV-2 are poorly understood. However, it seems to related to a systemic inflammatory response with a still unclear mechanism, and it is a reversible mechanism: in other words, it will resolve in few hours.

Very few anecdotal exceptions to this common non-severe and reversible post-vaccination headache have been described as case reports of complications of vaccination, specifically as cases of cerebral venous thrombosis associated with vaccine-induced immune thrombotic thrombocytopenia (VITT). The main differences from the normal vaccine-associated headache lies in the delayed onset (5-10 days), and headache being described as severe, progressive and treatment-resistant.

In sum, headache is a common side effect of vaccination after SARS-CoV-2, and it is almost always a non-severe effect. It presents within the first day and resolves within a day with bed rest or acetylsalicylic acid in 18-27% of the cases after the first dose, and in 23-35% after the second dose. It may have migrainous features in around a third of the cases, particularly among persons who already suffer from migraine.

Read the rest here:

Headache after vaccination against COVID-19 - On Medicine - BMC Blogs Network

(Precision Vaccinations)

A new study published by Wisconsin-based Epic Research quantifies how specific comorbidities could affect the risk of breakthrough COVID-19 cases, defined as getting an infection after being 'fullyvaccinated.'

Published on March 31, 2022, these Epic researchers used medical records to find pregnant womenare 1.91 times as likely to have a breakthrough infection.

And individuals with a solid organ transplant are 1.83 times as likely, and people withan immune system deficiency are 1.63 times as possible.

However, thisstudy did not find that cancer increased the risk of breakthrough infections.

These data come from Cosmos, a HIPAA-defined Limited Data Set of more than 140 million patientsfrom 161 Epic organizations, including 960 hospitals and 20,814 clinics, serving patients in all 50 states.

Two Epic teams completed this study, each composed of a clinician and research scientists who worked independently.

This study'sfindings support the U.S. CDC's recommendation that patients with high-risk comorbidity may need enhanced infection prevention control beyond vaccination to minimize the risk of future infection.

The CDCrecently stated, 'even if you are fully vaccinated andlive in an area with a highCOVID-19 Community Level infection rate, you will be better protected if you wear a mask in indoor public places.'

And, 'people who areimmunocompromisedmay not always build adequate levels of protection after an initial 3-dose primary mRNA COVID-19 vaccine series.'

Moreover, 'havingcertain underlying medical conditions and other factors, including age, can further increase the risk of getting very sick from COVID-19 during or at least 42 days following pregnancy.

As of February 19, 2022, the CDC's data dashboard presents COVID-19 vaccination among pregnant womenaged 18-49 years overall, by race/ethnicity, and when the women were vaccinated.

Note: The Epic study and CDC information were edited for clarity and manually curated for mobile readers.

See the article here:

COVID-19 Vaccinated Pregnant Women Found at High-Risk for Breakthrough Infection - Precision Vaccinations

A complaint initially filed in the Tennessee state court in February was removed to the federal counterpart on Thursday. The plaintiff sued his former employer, Tyson Foods, Inc. over their alleged violation of Tennessee COVID-19 laws. Specifically, he claims he was discharged from his job with Tyson over their misconception of him as unvaccinated and as retaliation for requesting workers compensation benefits.

In 2008, the plaintiff was hired by the defendant to work at their chicken processing factory in Union City, Tennessee. Throughout the fourteen years of his employment, the plaintiff contends he had no disciplinary action taken towards him.

The plaintiff received his first dose of the Moderna COVID-19 vaccination in April 2021 and his second dose just one month later. In the fall 2021, Tyson required all of their employees to provide proof of their COVID-19 vaccination, the complaint said. According to the complaint, the plaintiff had lost his vaccination card and immediately began to contact hospital, clinic, and state officials so that he could obtain the proper records.

The plaintiff said he was terminated on November 29, 2021, for not taking the vaccine. The termination occurred despite the plaintiff obtaining numerous records verifying his vaccination status and also [receiving] a replacement card from the State of Tennessee.

According to the complaint, the plaintiff showed the records to Tyson upon receiving notice of his termination, at which point he was reinstated but kept on unpaid suspension. After weeks of unpaid suspension, Tyson informed him that he was once again terminated for not taking the COVID-19 vaccination. The plaintiff said he asserted that he was vaccinated and had the corresponding proof.;Tyson then stated that the reason for his termination was gross misconduct.

The plaintiff maintains that the real reasons for his termination from Tyson were because of the defendants false perception that he was unvaccinated and as retaliation because he filed for workers compensation due to an arm and hand injury.

The plaintiff is seeking injunctive relief, damages, and any other relief deemed necessary by the court.

The plaintiff is represented by Spragins Barnett & Cobb, PLC.

Follow this link:

Former Employee Sues Tyson Foods Over COVID-19 Vaccination-Related Termination - Law Street Media

Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease  The Lancet

See original here:

Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease - The...

HOUSTON, TX U.S.Sen. Ted Cruz (R-Texas) this week introduced theGIVE LIFE Act(Dosss Bill) with Sen. Grassley (R-IA) and theEnding Discrimination in COVID-19 Treatments Act. Dosss Bill is named after a teenage Texan who was denied a kidney transplant because he had not been vaccinated against COVID-19. Both of these bills would ensure that Americans are not discriminated against while trying to access critical, life-saving care.

The GIVE LIFE Act would prohibit denying an individual from donating or receiving an organ because of their COVID-19 vaccination status, and from the number of COVID-19 cases in a region being used as a factor in determining eligibility to donate or receive an organ transplant.The GIVE LIFE Act would also prevent Medicare and Medicaid providers from denying services to individuals based on their COVID-19 vaccination status.

The Ending Discrimination in COVID-19 Treatments Act would mandate the Department of Health and Human Services (HHS) to require that providers receiving monoclonal antibodies do not engage in discriminatory practices such as considering someones race, color, religion, sex, national origin, age, religion, disability, vaccination status, veteran status, political ideology, or speech when allocating theantibodies. There have been reports that states across the country are using race and ethnicity as a factor in determining whether someone is eligible to receive monoclonal antibodies which are critical, life-saving therapies that aide in the recovery from COVID-19.

Upon introducing these bills, Sen. Cruz said:

No American should be denied a life-saving drug or organ because of their race, ethnicity, or COVID-19 vaccine status. That is wrong. Unfortunately, were seeing this kind of discrimination. My bills would prohibit the federal government from enabling this discrimination, so that every American has access to the care and treatment they needregardless of their COVID-19 vaccination status or any other contrived criteria.

Jon Schweppe, Director of Policy and Government Affairs at the American Principles Project said:

"COVID-19 has taken far too many American liveswe certainly shouldn't let it take America's soul. But a number of haughty eliteshave decided that they should be granted a license to discriminate against those who they view as lesser for not obeying the vaccine edicts of Anthony Fauci and Big Pharma. Everyone should get the vaccine, but if they don't want it, they shouldn't have to get it, and they certainly shouldn't face any sort of punitive treatment. The idea that medical professionals should be allowed to say who lives and who dies based on whether someone got the vaccine is not only un-American and discriminatory, but it would seem to violate the Hippocratic oath. We should be better than this. TheGIVE LIFE Act would safeguard access to life-saving treatment forall Americansit will save lives. American Principles Project is proud to endorse it."

Adam Brandon, President of FreedomWorks said:

The decision to take the COVID-19 vaccine belongs solely with the individual. It is beyond reprehensible for any person to be denied medical care based on their COVID-19 vaccination status.

Sen. Ted Cruz's GIVE LIFE Act will protect medical freedom while ensuring access to life-saving organ transplants. The COVID-19 regulatory madness must stop. We thank Senator Cruz for continuing to protect Americans medical freedom from the entrenched public health establishment.

###

View post:

Sen. Cruz Introduces Bills to Prevent COVID-19 Discrimination in Healthcare - Senator Ted Cruz

Each vaccine has its own risks and benefits, but those that have been approved for use are effective at reducing risk of a COVID-19 infection. The best vaccine for an individual is one they can access and feel comfortable taking.

The Food and Drug Administration (FDA) has approved or authorized three vaccines: Moderna, Pfizer-BioNTech, and Johnson & Johnsons Janssen. The Centers for Disease Control and Prevention (CDC) recommend getting Moderna or Pfizer-BioNTech if they are available.

However, different vaccines are available globally. Many countries are starting to approve the new Novavax vaccine and the Oxford AstraZeneca vaccine that is common in Europe.

Like all medical treatments and medications, vaccines come with risks and benefits.

The data on COVID-19 vaccines show that side effects are minimal. While there have been rare instances of serious side effects, the risk of adverse events from a COVID-19 infection is much higher.

Read more to learn about the approval status, dosage, efficacy, and side effects of each COVID-19 vaccine.

The Pfizer-BioNTech vaccine, also called COMIRNATY, is an mRNA vaccine.

It uses a lipid, or a fatty acid, to deliver a piece of the viruss genetic code. However, it does not contain the virus rather, it contains a piece of messenger RNA (mRNA) that codes for the viruss unique spike protein.

The body responds to this spike protein as an intruder and develops the immune reaction it needs to fight it. The vaccine teaches the body how to fight the COVID-19 virus when it encounters the real thing.

The vaccines contents leave the body and do not alter a persons genetic code.

It does not contain:

The FDA has approved the vaccine for individuals over the age of 16. It has an emergency use authorization for people over the age of 5 and for booster shots.

The initial series is two injections, at least 21 days apart, and a booster requires a third shot.

The dosage is:

It is safe to mix and match this vaccine with others.

The vaccines side effects are typically mild, and some people report having more side effects after the second vaccine.

They commonly report cold and flu-like symptoms such as:

The side effects usually disappear within a few days. They happen because of the immune systems reaction to the injection, so having side effects shows that the vaccine is working.

According to the CDC, the full series of the vaccine is more than 95% effective at preventing laboratory-confirmed COVID-19 infections in adults who are not immunocompromised and have no documented history of a COVID-19 infection.

In children ages 515 and people with immunocompromising conditions, the vaccine was at least 90% effective.

Among adults without immunocompromising conditions between March 11 and August 15, 2021, the vaccine offered 88% efficacy against hospitalization. This time period extends into the Delta wave of the pandemic.

Preliminary data from Pfizer showed that three doses of the vaccine could neutralize the Omicron variant.

Other research is still ongoing. A 2022 study found that in a lab setting, a booster could offer some immunity to Omicron.

The Moderna vaccine, also called Spikevax, is an mRNA vaccine

Although it works similarly to the Pfizer vaccine, it delivers a slightly higher dose.

Like Pfizer, it contains mRNA that gives instructions for fighting the spike protein on the COVID-19 virus. This produces an immune reaction that trains the body to fight the virus if it encounters it in the real world.

The vaccines contents leave the body and do not alter a persons genetic code. It does not contain any of the following:

The FDA has approved the Moderna vaccine for adults ages 18 and over. It also has an emergency use authorization as a one-dose booster 5 months after receiving another vaccine.

Moderna is not approved for use in children.

The initial Moderna series requires two injections, with a third shot as a booster.

It has earned an emergency use authorization for people over the age of 18. Each dose is 0.5 mL, and the two shots should be at least 28 days apart.

Like the Pfizer vaccine, it is safe to mix and match this vaccine with others.

Because they are both mRNA vaccines, the side effects of Moderna are similar to those of Pfizer.

Some people report mild cold or flu-like symptoms shortly after getting vaccinated with side effects more frequently appearing after the second vaccine than the first. Some common side effects include:

Among adults without immunocompromising conditions between March 11 and August 15, 2021, Moderna was 93% effective against hospitalization due to COVID-19. This time frame includes the Delta wave, but not Omicron.

A 2022 study found that an additional Moderna booster dose could provide some immunity against the Omicron variant while the two-dose series did not. Moderna is working on a booster specific to new variants.

The J&J/Janssen vaccine is a single-shot viral vector vaccine.

Unlike Pfizer and Moderna, it is not an mRNA vaccine. Instead, it works similarly to traditional vaccines.

The vaccine uses a weakened form of a harmless adenovirus that delivers genetic code for the unique COVID-19 spike protein. This creates an immune reaction that prepares the body to fight COVID-19. The vaccines contents leave the body and do not alter a persons genetic code.

It cannot infect a person with COVID-19 or the adenovirus, and it does not contain:

The injection is generally less effective than the Moderna and Pfizer vaccines.

The CDC urges people to choose the mRNA vaccines unless they are inaccessible. While J&J/Janssen is safer than going unvaccinated, it may have worse side effects than other vaccines.

The FDA has approved the vaccine on an emergency use authorization basis for people over the age of 18. It has also given emergency use authorization for a booster at least 2 months after the first dose.

The vaccine is not approved for children or anyone under the age of 18.

The most common side effects of this vaccine include mild cold or flu-like symptoms such as nausea, fever, chills, and muscle aches.

Very rarely, however, a person may develop a blood clot.

The CDC estimates that roughly 3.83 people per million will have this side effect. However, the blood clot rate is much higher with a COVID-19 infection, with as many as 1 in 5 people experiencing a blood clot. Of 18.2 million J&J/Janssen vaccine recipients, just 57, or 1 in more than 300,000, have reported blood clots.

The J&J/Janssen vaccine is a single-dose vaccine. It has an emergency use authorization in the United States for people over the age of 18.

A person can also get a single dose booster, but the CDC recommends choosing Pfizer or Moderna instead. It is safe to mix and match this vaccine with others.

Between March 11 and August 15, 2021, a time period that included the Delta wave but not Omicron, the J&J/Janssen vaccine was 71% effective in preventing COVID-19 hospitalization.

The Oxford AstraZeneca vaccine works very similarly to the J&J/Janssen vaccine.

It uses an adenovirus to deliver the COVID-19 spike protein into the body. This creates an immune reaction that trains the body to fight the virus if it encounters it again.

The AstraZeneca vaccine does not have FDA approval in the United States. However, it is popular in Europe because it is less expensive to produce than mRNA vaccines and is easier to store.

The World Health Organization (WHO) recommends two doses of 0.5 mL each, and the vaccines should be 8 to 12 weeks apart. It is safe to mix and match this vaccine with others.

Some common side effects include:

In rare cases, the AstraZeneca vaccine may cause blood clots. The risk of blood clots from COVID-19 is exponentially higher.

The AstraZeneca vaccine prevents symptomatic infection in 6 out of 10 people. Early trials, prior to Delta and Omicron, showed an 80% efficacy at preventing hospitalization.

The Novavax vaccine uses older vaccine technology specifically, a protein subunit.

This vaccine delivers an antigen synthesized from the COVID-19 spike protein to train the body to fight the virus. It does not contain a live virus, and the spike antigen cannot replicate.

Novavax is not yet approved for use in the U.S., but a request for an emergency use authorization has been submitted. As of November 2021, it is approved for use in Indonesia and the Philippines.

The WHO recommends two 0.5 mL doses given 34 weeks apart.

It is safe to mix and match this vaccine with others.

Side effects include:

In clinical trials, the efficacy of Novavax against mild, moderate, and severe disease was 90%. Researchers do not know if it prevents infection or transmission and are conducting additional research.

There are four types of COVID vaccines in use or in clinical trials:

Current CDC guidelines suggest that vaccines are safe for most people including those who are pregnant, breastfeeding, and have immunocompromising conditions. A person should only avoid a vaccine if they have had an allergic reaction to a specific ingredient in that vaccine.

The availability of vaccines varies from location to location. In areas that offer multiple vaccines, a person can often choose their vaccine. This might require going to a specific provider or scheduling the vaccine for a specific day.

It is usually safer to get the first available vaccine to maximize a persons protection against COVID-19.

All currently approved COVID-19 vaccines are safe for use and reduce a persons chance of severe illness with the virus.

Although all vaccines come with side effects, the risk of side effects from COVID-19 remains much higher. Except for a severe allergic reaction or a known allergy, there is no reason to avoid a COVID-19 vaccine.

Original post:

Which COVID-19 vaccine is best? Pfizer, Oxford, and more - Medical News Today